Monday, July 21, 2014
setbacks and a rapidly evolving HCV landscape have left AbbVie
Inc. less insulated from potential biosimilar
competition for blockbuster Humira adalimumab. Now that Shire plc has
decided to accept AbbVie's takeout bid, the specialty pharma's rare disease
portfolio and pipeline, along with its ADHD franchise, could help fill a
potential revenue gap.
offer since May, when the pharma started to privately court the
Irish company, values Shire at £31.4 billion ($54.5 billion) and is a 35%
premium to the biotech's first bid of £23.6 billion ($39.9 billion). The deal
is 46% cash and 54% stock.